Subventions et aides pour les organisations sociales

National Science Foundation Translation to Practice

États-Unis · US

Qui peut postuler Others (see text field entitled "Additional Information on Eligibility" for clarification)

The U.S. NSF Directorate for Technology, Innovation and Partnerships (NSF TIP) partners across sectors to advance three primary focus areas – accelerating technology translation and development, fostering regional innovation and economic growth, and preparing the American workforce for future high-wage jobs in STEM fields. The translation of research to practice ensures that the insights and innovations developed through scientific study and experimentation have tangible, positive impacts for the Nation. These impacts include improving the quality of life, promoting economic and job growth, ensuring national security, and maintaining global competitiveness. Indeed, scientific and engineering breakthroughs have the potential to address critical societal challenges in industries such as aerospace, agriculture, communications, education, energy, healthcare, national security, and transportation – but the translation of discoveries and innovations from the laboratory to society often takes many forms including non-linear pathways. The NSF TTP program was developed with several goals in mind: To identify and support use-inspired research and translational activities enabling a continuum from foundational research to practice; To develop partnerships and collaborations between institutions of higher education and other entities (e.g., industry, state/local/national government agencies, philanthropies, open-source ecosystems, for-benefit, for-profit and non-profit organizations, international organizations, etc.); To promote and advance the education and training of students and postdoctoral researchers, encouraging the participation of all Americans in STEM including innovation and entrepreneurship; and To identify future customer needs and opportunities and bring these to the forefront in the conduct of use-inspired research and translational activities. The NSF TTP program offers three tracks that represent different starting points or stages in moving discoveries and innovations from the laboratory to practice: NSF TTP-Explore (NSF TTP-E) is a pilot track that is likely to be the first step for researchers seeking to translate their basic research to practice. To be eligible for the NSF TTP-E track, proposers must have an active, eligible, NSF research award (see Eligibility Information for further details). TTP-E is designed to encourage current, eligible NSF awardees to intentionally pursue applications of their research with the potential for societal impact. The NSF TTP-E track provides the opportunity to obtain an extension of the initial award period of a current NSF award for up to two years in order to offer investigators an opportunity to explore adventurous, high-risk, use-inspired research and initial translational activities as the starting point for translation that was not covered by the original research award. NSF TTP-Translate (NSF TTP-T) starts with use-inspired research and initial translational activities and further matures the idea(s), iterates and improves the solution(s), and lowers the barrier(s) to effective translation of research from lab to practice. NSF TTP-Partner (NSF TTP-P) supports translational efforts that demand one or more partnerships for technology development and deployment. Here, strategic partnerships with stakeholders beyond U.S. institutions of higher education are essential ingredients for success and may include industry partners, government entities at all levels, philanthropies, international organizations, or other groups associated with large scale productization and distribution. The NSF TTP-P track requires an NSF-Catalyzed Partnership with an organization that will assist in the translation to practice. In addition to the Principal Investigator (PI), NSF TTP-P proposals must include a co-PI or Senior/Key Personnel who is a member or employee of the NSF-Catalyzed Partner. Partnerships with U.S. institutions of higher education are valued, but NSF TTP strongly prioritizes NSF-Catalyzed Partnerships that are able to help bring the product, process, or service to the market, potentially through licensing agreements, startup or small business formation, incorporation into an existing open-source ecosystem, development into standards setting arrangements, etc.

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)

États-Unis · US

Qui peut postuler Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Special district governments · Public housing authorities/Indian housing authorities · County governments · Independent school districts · Public and State controlled institutions of higher education · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Private institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification) · City or township governments · For profit organizations other than small businesses · Native American tribal organizations (other than Federally recognized tribal governments) · Native American tribal governments (Federally recognized) · State governments · Small businesses

This Notice of Funding Opportunity (NOFO) focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this NOFO is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and that (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. The R61 phase will support pilot studies or secondary data analysis for hypothesis development and feasibility, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R61 phase. Highest priority will be given to applications with clinical trials. Applicants interested in planning clinical trials or adding to current projects may also consider NOFO (TEMP-23832, the R34 option).

Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)

États-Unis · US

Qui peut postuler Public and State controlled institutions of higher education · Private institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification) · County governments · Native American tribal governments (Federally recognized) · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Special district governments · State governments · Small businesses · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Independent school districts · City or township governments · Native American tribal organizations (other than Federally recognized tribal governments) · Public housing authorities/Indian housing authorities · For profit organizations other than small businesses

The goal of this notice of funding opportunity (NOFO) is to support feasibility trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) for conditions that have been identified by NCCIH as high-priority research topics. This funding opportunity is intended to support feasibility clinical trials that provide new information that are scientifically necessary for the planning and conduct of a subsequent clinical efficacy or effectiveness study, pragmatic trial, or dissemination and implementation trial within NCCIHs mission. NCCIH expects that applications to this NOFO will describe the planned future clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent competitive full-scale clinical trial. Under this R34, the data collected should be used to fill gaps in scientific knowledge necessary to develop a competitive full-scale clinical trial, including, but not limited to the following: examining feasibility and acceptability of interventions lacking published data; tailoring or adapting the content or structure of an intervention to a specific population, modality, or setting; refining the intervention to determine the most appropriate frequency or duration; determining feasibility of recruitment, retention, and data collection procedures; refining and assessing the feasibility of protocolized multi-component interventions; or examining acceptability and adherence of control conditions. The subsequent full-scale clinical trial should have the potential to make a significant impact on public health. Prior to submitting to this NOFO, applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact person for the science area of the planned application.

Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)

États-Unis · US

Qui peut postuler Native American tribal organizations (other than Federally recognized tribal governments) · For profit organizations other than small businesses · County governments · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Small businesses · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Native American tribal governments (Federally recognized) · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Private institutions of higher education · Special district governments · Independent school districts · Public and State controlled institutions of higher education · State governments · City or township governments · Public housing authorities/Indian housing authorities

This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated fully remotely delivered and conducted clinical trials to assess the efficacy or effectiveness of complementary and integrative health interventions in NCCIH- designated areas of high research priority. Applications submitted under this NOFO are expected to propose a remotely delivered and conducted fully powered clinical trial with no in-person contact between research staff and study participants and may utilize mHealth tools or technologies. Applicants must provide justification for the remotely delivered approach and provide preliminary data on the feasibility and safety of the approach, along with evidence that the intervention has promise of clinical benefit. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this NOFO.

NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)

États-Unis · US

Qui peut postuler For profit organizations other than small businesses · Independent school districts · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · State governments · Native American tribal organizations (other than Federally recognized tribal governments) · Special district governments · Public and State controlled institutions of higher education · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Private institutions of higher education · Small businesses · County governments · City or township governments · Public housing authorities/Indian housing authorities · Native American tribal governments (Federally recognized) · Others (see text field entitled "Additional Information on Eligibility" for clarification)

This notice of funding opportunity (NOFO) invites applications for investigator-initiated clinical trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) in NCCIH-designated areas of high research priority. Applications submitted under this NOFO are expected to propose a multisite feasibility clinical trial that will provide new information that is scientifically necessary for the planning and conduct of a subsequent clinical efficacy or effectiveness study, pragmatic trial, or dissemination and implementation trial within NCCIHs mission. NCCIH expects that applications to this NOFO will describe the planned future clinical trial and in so doing demonstrate that the proposed (R01) research is scientifically necessary to design or plan the subsequent fully powered, full-scale clinical trial. Under this R01, the data collected should be used to fill gaps in scientific knowledge, including, but not limited to the following: assessing whether the intervention can be delivered with fidelity across sites; demonstrating feasibility of recruitment, accrual, and randomization of participants across sites; demonstrating participant adherence to the intervention, as well as retention of participants throughout the study across sites; refining and assessing the feasibility of protocolized multimodal interventions, and/or demonstrating feasibility of data collection across sites in preparation for a future fully powered, multisite efficacy or effectiveness trial. The need for multisite feasibility trials is expected to be justified by sufficient preliminary data from previous single site feasibility or acceptability trial(s) or the published literature. The data collected should be used to fill gaps in scientific knowledge and be necessary to develop a competitive fully powered multisite clinical trial that has the potential to make a significant impact on public health.

Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)

États-Unis · US

Qui peut postuler Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Native American tribal governments (Federally recognized) · Special district governments · Private institutions of higher education · State governments · For profit organizations other than small businesses · Public and State controlled institutions of higher education · City or township governments · County governments · Independent school districts · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Native American tribal organizations (other than Federally recognized tribal governments) · Small businesses · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Public housing authorities/Indian housing authorities

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) along with other participating Institutes encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. Applicants are encouraged to leverage and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in cancer research.

PRIMERA CONVOCATORIA DEL PROGRAMA DE INCENTIVOS A PROYECTOS SINGULARES INNOVADORES DE AHORRO Y EFICIENCIA ENERGÉTICA (INNOVAE)

ESTADO - MINISTERIO PARA LA TRANSICIÓN ECOLÓGICA Y EL RETO DEMOGRÁFICO - INSTITUTO PARA LA DIVERSIFICACIÓN Y AHORRO DE LA ENERGÍA (IDAE) ·

Industria y Energía

Période : 15/9/2026 – —

DOW Combat Readiness – Medical Research Program Translational Research Award

États-Unis · US

Qui peut postuler Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Summary: The fiscal year 2026 (FY26) Combat Readiness – Medical Research Program (CRRP) Translational Research Award (TRA) supports hypothesis-driven innovative, high-impact translational research that will accelerate the movement of promising ideas and/or technologies in trauma care into solutions to maximize casualty survivability, improve patient care closer to the point of injury and/or trauma care guidelines. Preliminary data are required. Research using well-validated animal models is allowed. Distinctive Features: • **NEW for FY26** An investigator may be named as the Principal Investigator (PI) on only one FY26 CRRP TRA application. • Research supported by the FY26 CRRP TRA must represent a mature, translational research effort with a minimum biomedical technology readiness level (TRL) of 4 or knowledge readiness level (KRL) of 4.

DoW Orthopaedic, Clinical Research Award

États-Unis · US

Qui peut postuler Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Summary: The fiscal year 2026 (FY26) Orthopaedic Research Program (ORP) Clinical Research Award (CRA) seeks clinical research that evaluates orthopaedic-specific factors and interventions. The ORP intends for research supported by this mechanism to generate clinically useful evidence with potential to optimize patient outcomes and inform clinical care or policy. Applications must address how the proposed research will impact patient care and reduce the burden of orthopaedic injury and sequela. The ORP expects that research findings benefit Service Members, their families, Veterans and the general public. To meet the intent of the award mechanism, applications must specifically address at least one of the FY26 ORP CRA Focus Areas. Distinctive Features: · The CRA offers two research levels. Research Level 1 (RL1) supports clinical research in the following FY26 ORP focus areas: · Ligamentous Trauma · Osseointegration Outcomes · Return-to-Duty Strategies · Military Women’s Health Research Level 2 (RL2) supports clinical trials in the following FY26 ORP focus areas: · Ligamentous Trauma · Limb Stabilization and Protection · Return-to-Duty Strategies

DoW Orthopaedic, Applied Research Award

États-Unis · US

Qui peut postuler Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Summary: The Orthopaedic Research Program (ORP) Applied Research Award (ARA) seeks applied research applications focused on advancing optimal treatment and restoration of function for individuals with orthopaedic injuries sustained during combat or service-related activities. Distinctive Features: • Applied research is defined as work that refines concepts and ideas into potential solutions with a view toward evaluating technical feasibility of promising new knowledge products, pharmacologic agents, behavioral and rehabilitation interventions, diagnostic and therapeutic techniques, clinical guidance and/or emerging approaches and technologies. • Preliminary data is required. • Military relevance : the ORP expects that research findings benefit Service Members, their families, Veterans and the general public. • Clinical research is not allowed.

DoW Rare Cancers Resource and Community Development Award

États-Unis · US

Qui peut postuler Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Summary: The fiscal year 2026 (FY26) Rare Cancers Research Program (RCRP) Resource and Community Development Award (RCDA) supports the development of research resources and clinical or preclinical datasets that will advance the field of rare cancers research and ultimately improve outcomes for individuals with rare cancers. Research supporting this funding opportunity should fill one of the following major gaps: Lack of research and clinical resources, including patient tissues, cell and tumor models. Lack of communication and dissemination strategies within scientific and patient communities for sharing rare cancers research and clinical findings. Lack of infrastructure for sharing data and other resources. Lack of therapeutics and mechanistic research to inform treatment development. Distinctive Features: Documentation of plans for engagement and partnerships with Patient Advocates throughout the life cycle of the research study from development of the research question through execution of the study. Community building and enhancement are key components. A description of the dissemination and sustainability of the platform for scientific and/or clinical and patient community is required. Preliminary data are not required but may be included to address feasibility.

DoW Rare Cancers Idea Development Award

États-Unis · US

Qui peut postuler Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Summary: The fiscal year 2026 (FY26) Rare Cancers Research Program (RCRP) Idea Development Award (IDA) promotes ideas that are ready for further development and have the potential to yield high-impact findings and new avenues of investigation. Distinctive Features: The RCRP encourages applicants to include an exploratory aim or sub-aim to support any necessary discovery-driven research. Preliminary data with disease-specific rationale are required. However, these data do not necessarily need to originate from studies of the proposed rare cancer type(s)/subtype(s) under study. Research should have high potential impact on rare cancers and the patient community.

National Science Foundation Fostering Interdisciplinary Networks to Develop Emergent and Responsive Solutions Foundry

États-Unis · US

Qui peut postuler Others (see text field entitled "Additional Information on Eligibility" for clarification)

The NSF FINDERS FOUNDRY program supports collaboration among K-12 educators, technologists, and researchers to develop innovative solutions to persistent challenges in learning and workforce development. These challenges are identified by K-12 students, families, and educators. The program aims to create and scale evidence-based practices, tools, and technologies that improve learning outcomes and prepare students for a digital, Artificial Intelligence (AI)-driven future. A key focus is early exposure to AI to build curiosity, understanding, and readiness for future careers. The program encourages partnerships across sectors - schools, universities, industry, government, and nonprofits - to co-design responsive, technology-based solutions. NSF FINDERS FOUNDRY program includes two phases: Planning and Development. Planning proposals help teams explore one of several focus areas. Only teams awarded Planning grants may submit Development proposals, which support the growth and implementation of promising ideas. The program aligns with national priorities, including the Executive Order 14277, “Advancing Artificial Intelligence Education for American Youth ” (April 23, 2025), and the CHIPS and Science Act of 2022, Public Law 117-167 , Sections 10381-10383 and 10395.

Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)

États-Unis · US

Qui peut postuler County governments · Native American tribal organizations (other than Federally recognized tribal governments) · Public housing authorities/Indian housing authorities · Special district governments · For profit organizations other than small businesses · Public and State controlled institutions of higher education · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · State governments · Small businesses · Native American tribal governments (Federally recognized) · Private institutions of higher education · Independent school districts · Others (see text field entitled "Additional Information on Eligibility" for clarification) · City or township governments · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education

The purpose of this NOFO is to invite Research Project (R01) applications that propose to study the ethical, legal, and social implications (ELSI) of human genetics and genomics. Applications may propose studies using either single or mixed methods. Approaches may include but are not limited to empirical qualitative and quantitative methods, as well as conceptual, legal, and normative analyses. Direct involvement of key stakeholders where appropriate is encouraged. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Applications without a PEDP will not be reviewed.

Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)

États-Unis · US

Qui peut postuler State governments · Public and State controlled institutions of higher education · Private institutions of higher education · Public housing authorities/Indian housing authorities · Others (see text field entitled "Additional Information on Eligibility" for clarification) · For profit organizations other than small businesses · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Native American tribal governments (Federally recognized) · Small businesses · Independent school districts · County governments · Native American tribal organizations (other than Federally recognized tribal governments) · City or township governments · Special district governments

The purpose of this NOFO is to invite Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal, and social implications (ELSI) of human genetics and genomics. Applications may propose studies using either single or mixed methods. Approaches may include but are not limited to empirical qualitative and quantitative methods, as well as conceptual, legal, and normative analyses. Direct involvement of key stakeholders where appropriate is encouraged. Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information.

DoW Toxic Exposures Investigator Initiated Research Award

États-Unis · US

Qui peut postuler Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Summary: The fiscal year 2026 Toxic Exposures Research Program (TERP) Investigator-Initiated Research Award (IIRA) is intended to support studies that will make an important contribution toward research and/or patient care for diseases or conditions associated with military-related toxic exposures. Research projects may focus on any phase of research from basic laboratory research through translational research, including preclinical studies in animal models and human subjects, as well as correlative studies associated with an existing clinical trial. New Approach Methodologies may also be used. https://cdmrp.health.mil/pubs/press/2026/terppreann

DoW Toxic Exposures Translational Research Award

États-Unis · US

Qui peut postuler Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Summary: The intent of the fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Translational Research Award (TRA) is to support translational research that will accelerate the movement of promising ideas in military-related toxic exposure research into clinical applications, including health care products, interventions, technologies and/or clinical practice guidelines. Translational research may be defined as an integration of basic science and clinical observations. New Approach Methodologies may also be used. Applications should provide evidence for the reciprocal transfer of information between basic and clinical science, or vice versa, in developing and implementing the research plan. Distinctive Features: To encourage applications that include meaningful and productive collaborations, the FY26 TERP TRA includes a Partnering Principal Investigator Option (PPIO). One Principal Investigator (PI) is identified as the initiating PI, and an additional PI may be identified as a Partnering PI. If recommended for funding, each PI will be named on separate awards. The intent is to support interdisciplinary partnerships, such as those between clinicians and research scientists, that will accelerate the movement of promising ideas into clinical applications. Partnering should significantly advance the research beyond what would be possible through individual efforts. https://cdmrp.health.mil/pubs/press/2026/terppreann

DoW Toxic Exposures Clinical Trial Award

États-Unis · US

Qui peut postuler Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Summary: The fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Clinical Trial Award (CTA) mechanism supports the advancement, execution, and analysis of clinical trials with the potential to have a significant impact on the prevention, treatment, or management of symptoms, diseases or conditions associated with or resulting from military-related toxic exposures. Proposed projects may range from small proof-of-concept clinical trials (e.g., pilot, first-in-human, phase 0) designed to demonstrate the feasibility or inform the design of more advanced trials, through large-scale trials (including pragmatic clinical trials) to determine efficacy in relevant patient populations. Distinctive Features: To encourage applications that include meaningful and productive collaborations, the FY26 TERP CTA includes a Partnering Principal Investigator Option (PPIO) . One Principal Investigator (PI) is identified as the initiating PI, and an additional PI may be identified as a Partnering PI. If recommended for funding, each PI will be named on separate awards. The intent is to support interdisciplinary partnerships, such as those between clinicians and research scientists, that will accelerate the movement of promising interventions/​knowledge products into clinical applications. Partnering should significantly advance the research beyond what would be possible through independent efforts. https://cdmrp.health.mil/pubs/press/2026/terppreann

Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

États-Unis · US

Qui peut postuler City or township governments · Native American tribal organizations (other than Federally recognized tribal governments) · Private institutions of higher education · For profit organizations other than small businesses · Native American tribal governments (Federally recognized) · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Public and State controlled institutions of higher education · Independent school districts · Public housing authorities/Indian housing authorities · Special district governments · Small businesses · County governments · State governments · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education

The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD). Candidate interventions evaluated through this program, which can include small molecules or biologics for example, must engage non-amyloid/non-tau mechanisms and aim to address cognitive and/or neuropsychiatric symptoms in individuals across the spectrum from pre-symptomatic to more severe stages of disease. This NOFO uses the UG3/UH3 phased award mechanism and proposals must include prespecified, go/no-go safety and tolerability milestones that gate the advance from phase 1 to latter stages of clinical development.

NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)

États-Unis · US

Qui peut postuler City or township governments · Special district governments · Public housing authorities/Indian housing authorities · Native American tribal governments (Federally recognized) · Independent school districts · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Public and State controlled institutions of higher education · County governments · Native American tribal organizations (other than Federally recognized tribal governments) · Private institutions of higher education · State governments · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Small businesses · For profit organizations other than small businesses

This NOFO encourages applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions; biomarker or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery; and ancillary studies designed to add scientific aims to active studies being conducted within StrokeNet. Successful applicants will collaborate and conduct the study within the NIH StrokeNet. Following peer review, NINDS will prioritize studies among the highest scoring to be conducted in the NIH StrokeNet infrastructure. The NIH StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement the proposed study efficiently and the National Data Management Center (NDMC) will provide statistical and data management support. The NIH StrokeNet Regional Coordinating Centers (RCCs) and their affiliated clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.

Decreto Foral 73/2026, de 23 de julio, de la Diputación Foral de Bizkaia, por el que se aprueban las bases reguladoras y la convocatoria de los Premios al Reto de Periodismo de Datos 2026.

LOCAL - DIPUTACIÓN FORAL DE BIZKAIA - DIPUTACIÓN FORAL DE BIZKAIA ·

Educación

Période : 28/7/2026 – —

Convocatoria de ayudas para la elaboración de Trabajos Fin de Grado y Trabajos de Fin de Máster del Instituto de Investigación en Energías Renovables de la Universidad de Castilla-La Mancha del curso académico 2026/2027

OTROS - UNIVERSIDAD DE CASTILLA-LA MANCHA ·

Educación

Période : 15/9/2026 – —

III CONCURSO PROVINCIAL DE BELENES DE LA DIPUTACIÓN PROVINCIAL DE GRANADA. Navidad 2026 – 2027

LOCAL - DIPUTACIÓN PROV. DE GRANADA - DIPUTACIÓN PROVINCIAL DE GRANADA ·

Cultura

CONVOCATORIA SUBVENCIONES CONCURRENCIA COMPETITIVA PARA GASTOS VIVIENDA DE PERSONAS PROPIETARIAS, AÑO 2026

LOCAL - GARRIGA, LA - AYUNTAMIENTO DE GARRIGA, LA ·

Otras Prestaciones económicas

Période : 10/6/2026 – —